Real-time enrollment status for this bladder (urothelial, transitional cell) cancer clinical trial
Current Status
Recruiting
Checked: October 14, 2026 at 4:57 AM UTC
| NCT Number | NCT07725796 |
| Recruiting Status | Recruiting |
| Condition | Bladder (Urothelial, Transitional Cell) Cancer |
| Phase | PHASE1 |
| Target Enrollment | 30 participants |
| Active Locations | 15 sites in the US |
| Sponsor | UroGen Pharma, Inc., a subsidiary of UroGen Pharma Ltd. |
| Last Updated on CT.gov | October 13, 2026 (Yesterday) |
As of October 14, 2026: Clinical trial NCT07725796 is currently recruiting participants. This phase1 study for bladder (urothelial, transitional cell) cancer is actively seeking new participants at 15 locations across the United States. The study is sponsored by UroGen Pharma, Inc., a subsidiary of UroGen Pharma Ltd.. This status information is automatically verified from the official ClinicalTrials.gov registry.
Yes, NCT07725796 is actively recruiting participants as of October 14, 2026. You can check eligibility and apply through HelloStudys.
This trial is recruiting at 15 locations in the United States. View all available locations on the full study page.
Check your eligibility and express interest by completing the application form on the study page. A research coordinator will follow up to discuss next steps.
The official ClinicalTrials.gov record for NCT07725796 was last updated Yesterday (October 13, 2026). HelloStudys verifies this status automatically.